Kershaw V. Patel

Dec 5, 2024 | digitalcommons.library.tmc.edu | Byron C. Jaeger |Matthew W. Segar |Kershaw V. Patel |Vijay Nambi

BACKGROUND: Heart failure (HF) risk and the underlying risk factors vary by race. Traditional models for HF risk prediction treat race as a covariate in risk prediction and do not account for significant parameters such as cardiac biomarkers. Machine learning (ML) may offer advantages over traditional modeling techniques to develop race-specific HF risk prediction models and to elucidate important contributors of HF development across races.

Sep 6, 2024 | onlinelibrary.wiley.com | Matthew W. Segar |Muhammad Usman |Kershaw V. Patel |Muhammad Khan

Introduction Individuals with type 2 diabetes (T2D) have a significantly higher risk of heart failure (HF) than those without T2D despite optimal control of other risk factors.1-3 Thus, there has been an increased focus on developing novel approaches to reduce HF risk in this population.4 Targeted allocation of effective preventive interventions is contingent upon identifying patients at the highest risk of developing HF.

Mar 4, 2024 | onlinelibrary.wiley.com | Zainali S. Chunawala |Neil Keshvani |Matthew W. Segar |Kershaw V. Patel

Research Letter Association of diabetes-specific heart failure risk score with presence of subclinical cardiomyopathy among individuals with diabetes: A prospective study Zainali S. Chunawala,  Zainali S.

Mar 1, 2024 | jacc.org | Matthew W. Segar |Muhammad Khan |Kershaw V. Patel |Javed Butler

References1. "Heart disease and stroke statistics—2021 update: a report from the American Heart Association". Circulation . 2021;143:8: e254-e743. 2. "Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry". Cardiology . 2009;113:12-19. 3. "Diuretic therapy for patients with heart failure: JACC state-of-the-art review". J Am Coll Cardiol . 2020;75:1178-1195. 4.

Nov 11, 2023 | ahajournals.org | Kershaw V. Patel |Matthew W. Segar |David C. Klonoff |Muhammad Khan

Background: The optimal approach to identify individuals with diabetes who are at high-risk for developing heart failure (HF) to inform implementation of preventive therapies is unknown, especially in those without atherosclerotic cardiovascular disease (ASCVD). Methods: Adults with diabetes and no HF at baseline from 7 community-based cohorts were included.